Philogen S.p.A. (BIT: PHIL)
Health Care · Biotechnology · IT
€23.45
-0.42% today · -1.1% 1Y
Philogen S.p.A. (BIT: PHIL) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.10B and employs 214 people.
Over the last twelve months the share price has lost 1.1%, trading between 19.56 and 26.00.
Tweenvest scores Philogen S.p.A. across four factors: quality 78/100, value 51/100, growth 100/100, dividend 76/100. Its strongest factor is growth.
PHIL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.10B
- Revenue (TTM)
- $375.40M
- P/E
- 4.11
- EPS
- 5.70
- Dividend yield
- 2.97%
- Beta (5Y)
- -0.02
- 52-week high
- €26.00
- 52-week low
- €19.56
- Avg volume (3M)
- —
- Shares outstanding
- 40.28M
- Employees
- 214
- Next earnings
- —
About Philogen S.p.A.
Philogen S.p.A. is a biotechnology firm dedicated to creating therapeutic agents for cancer and persistent inflammatory conditions. Among its pipeline, Nidlegy is being developed as an intralesional therapy for localized melanoma and non-melanoma skin cancers, combining the immunocytokines L19IL2 and L19TNF. Another key product is Fibromun, a human immunomodulatory agent composed of the L19 antibody and TNF, aimed at treating soft tissue sarcoma, leiomyosarcoma, and glioma. Darleukin, also known as L19IL2, is a human immunostimulatory product that integrates the human L19 antibody with the human cytokine interleukin-2 (IL2); it is currently undergoing Phase II clinical trials for addressing non-small cell lung cancer. The company's developmental efforts also include Dodekin, a human immunostimulatory product in Phase I/II clinical trials, consisting of a vascular targeting antibody fused with interleukin-12, designed to combat advanced solid tumors. For chronic inflammation, Dekavil (F8IL10), an anti-inflammatory compound, is in Phase I clinical trials. Furthermore, Philogen is advancing diagnostic radiotracers: Onco IX (PHC-102), a 99mTc labelled small molecule, is in Phase I, intended for the non-invasive detection of solid tumors that express carbonic anhydrase IX (CAIX). Similarly, OncoFAP, another small molecule radiotracer, is also in Phase I, focusing on the non-invasive identification of various metastatic solid tumors by targeting fibroblast activation protein. Established in 1996, Philogen S.p.A. operates from its headquarters in Sovicille, Italy.
- ISIN
- IT0005373789
- Founded
- 1996
- Listed since
- Mar 3, 2021
- Exchange
- Borsa Italiana
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.